Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on July 11, 2023. The filing reports on a corporate governance event involving the amendment of an executive employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change reported is the execution of a Second Amendment to the Employment Agreement of Chief Financial Officer Marc Benathen, effective July 11, 2023. Key changes include:
- Cancellation of Prior Awards: Cancellation of 200,000 stock options and 250,000 performance share units previously granted.
- New Restricted Stock Awards:
- 125,000 restricted shares (50,000 vesting Jan 1, 2024; 75,000 vesting Jan 1, 2025).
- 261,250 restricted shares tied to net revenue and adjusted EBITDA margin milestones over four years.
- 150,000 restricted shares tied to personal performance over two years.
- Acceleration: Immediate acceleration of vesting for 25,000 previously granted restricted stock units.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on business outlook. However, it outlines specific contingencies regarding the new awards:
- Forfeiture: Unvested awards are forfeited upon termination for "Cause."
- Acceleration Triggers: 100% of awards vest immediately in the event of termination without "Cause," for "Good Reason," or upon a "Change of Control."
Investor Verification Checklist
- Review the full text of the Second Amendment to the Employment Agreement (Exhibit 10.3) for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Examine the Restricted Stock Award Agreement (Exhibit 10.4) to understand the specific net revenue and adjusted EBITDA margin targets required for the 261,250 milestone shares.
- Verify the impact of the cancelled options and performance units on the company's total share count and dilution.